润达医疗(603108) - 2024 Q3 - 季度财报

Revenue and Profitability - Revenue for the third quarter decreased by 13.84% year-over-year, with total revenue reaching 6,176,286,324.36 RMB, a year-to-date decrease of 10.36%[2] - Net profit attributable to shareholders of the listed company dropped by 137.69% year-over-year for the third quarter, with a year-to-date net profit of 50,424,910.92 RMB, down 82.21%[2] - Total operating revenue for the first three quarters of 2024 was RMB 6,176,286,324.36, a decrease of 10.36% compared to RMB 6,890,332,466.40 in the same period of 2023[18] - Net profit attributable to the parent company's shareholders for the first three quarters of 2024 was RMB 50,424,910.92, a significant decrease of 82.21% compared to RMB 283,453,202.57 in the same period of 2023[22] - Revenue for the first three quarters of 2024 was RMB 1,294,991,244.54, a decrease of 42.1% compared to RMB 2,235,857,829.07 in the same period of 2023[29] - Operating profit for the first three quarters of 2024 was RMB 8,261,138.58, a significant drop from RMB 176,006,091.97 in the same period of 2023[30] - Net profit for the first three quarters of 2024 was RMB 14,557,299.52, compared to RMB 180,107,764.21 in the same period of 2023[30] Earnings Per Share (EPS) - Basic earnings per share (EPS) for the third quarter were -0.07 RMB, a decrease of 136.84% year-over-year[3] - Basic earnings per share for the first three quarters of 2024 were RMB 0.08, down 83.67% from RMB 0.49 in the same period of 2023[23] - Basic earnings per share for the first three quarters of 2024 were RMB 0.02, down from RMB 0.31 in the same period of 2023[30] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were RMB 4,592,846,859.28, down 10.11% from RMB 5,109,831,024.35 in the same period of 2023[18] - The company's operating costs did not decrease proportionally with revenue, further affecting profitability[8] - R&D expenses for the first three quarters of 2024 were RMB 81,276,813.53, a decrease of 21.22% compared to RMB 103,178,932.82 in the same period of 2023[18] Cash Flow and Liquidity - Operating cash flow for the year-to-date increased by 12.99% to 208,487,607.14 RMB[2] - Cash received from sales of goods and services in the first three quarters of 2024 was RMB 7,406,130,055.09, a slight decrease of 2.14% from RMB 7,568,518,985.69 in the same period of 2023[24] - Cash paid for goods and services in the first three quarters of 2024 was RMB 5,741,070,855.72, a slight decrease of 0.79% from RMB 5,786,996,990.39 in the same period of 2023[24] - Operating cash flow increased to 208,487,607.14 in Q3 2024, up from 184,520,267.81 in the previous period[25] - Net cash flow from financing activities turned positive at 51,465,972.24, compared to a negative -155,375,513.39 in the previous period[25] - Cash flow from operating activities for the first three quarters of 2024 was negative RMB 392,081,178.64, compared to positive RMB 241,511,156.96 in the same period of 2023[31] - Cash flow from investing activities for the first three quarters of 2024 was positive RMB 179,301,515.47, an increase from RMB 80,568,694.77 in the same period of 2023[31] - Cash flow from financing activities for the first three quarters of 2024 was positive RMB 230,642,952.33, compared to negative RMB 339,602,272.39 in the same period of 2023[31] - Total cash and cash equivalents at the end of the third quarter of 2024 were RMB 78,637,754.89, up from RMB 43,935,410.87 at the end of the same period in 2023[31] Assets and Liabilities - Total assets as of the end of the reporting period were 14,361,164,907.93 RMB, a slight increase of 0.36% compared to the end of the previous year[3] - Total assets grew to 8,496,828,306.32 as of September 30, 2024, up from 8,068,649,586.26 at the end of 2023[26] - Accounts receivable decreased to 1,139,809,345.70, down from 1,320,810,853.41 at the end of 2023[26] - Prepayments increased significantly to 1,414,438,728.31, more than double the 582,237,837.82 at the end of 2023[26] - Inventory decreased to 190,664,144.26, down from 383,639,633.70 at the end of 2023[26] - Total liabilities increased to 5,695,303,704.12, up from 5,241,745,365.60 at the end of 2023[27] - Short-term borrowings rose to 1,573,886,915.14, up from 1,324,854,032.14 at the end of 2023[27] - Equity decreased slightly to 2,801,524,602.20, down from 2,826,904,220.66 at the end of 2023[28] - Retained earnings decreased to 681,298,404.98, down from 726,627,397.66 at the end of 2023[28] Non-Recurring Items and Government Subsidies - Non-recurring gains and losses for the period amounted to 5,766,516.18 RMB, with government subsidies contributing 6,750,451.40 RMB[4][5] Credit Impairment and Investment Income - The company's gross margin remained relatively stable, but credit impairment losses increased significantly compared to the same period last year, impacting net profit[6] - Historical payment cycles from some hospital customers have lengthened, contributing to higher credit impairment losses[6] - Credit impairment losses for the first three quarters of 2024 were RMB -112,898,735.77, an increase of 66.94% compared to RMB -67,614,867.79 in the same period of 2023[18] - Investment income for the first three quarters of 2024 was RMB 97,818,515.41, a decrease of 48.59% compared to RMB 190,288,942.37 in the same period of 2023[18] Business Expansion and Costs - The company has been investing in new business expansion, leading to increased marginal costs[6] Comprehensive Income - Total comprehensive income for the first three quarters of 2024 was RMB 144,214,102.93, down 64.92% from RMB 411,095,919.44 in the same period of 2023[23]